Clinitech Laboratory Ltd
Incorporated in 1990, Clinitech Laboratory Ltd is in the business of providing pathology and related healthcare services.[1]
- Market Cap ₹ 7.30 Cr.
- Current Price ₹ 32.0
- High / Low ₹ 47.2 / 28.6
- Stock P/E 17.4
- Book Value ₹ 40.5
- Dividend Yield 0.00 %
- ROCE 7.27 %
- ROE 4.65 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.79 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 5.94% over last 3 years.
- Debtor days have increased from 57.9 to 71.2 days.
- Working capital days have increased from 99.9 days to 164 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 4.55 | 6.38 | 6.35 | 6.40 | 8.23 | 9.48 | |
| 3.72 | 5.31 | 4.99 | 5.41 | 7.40 | 8.49 | |
| Operating Profit | 0.83 | 1.07 | 1.36 | 0.99 | 0.83 | 0.99 |
| OPM % | 18.24% | 16.77% | 21.42% | 15.47% | 10.09% | 10.44% |
| 0.04 | 0.07 | 0.02 | 0.04 | 0.23 | 0.19 | |
| Interest | 0.08 | 0.06 | 0.07 | 0.09 | 0.06 | 0.07 |
| Depreciation | 0.25 | 0.38 | 0.45 | 0.44 | 0.45 | 0.51 |
| Profit before tax | 0.54 | 0.70 | 0.86 | 0.50 | 0.55 | 0.60 |
| Tax % | 25.93% | 27.14% | 29.07% | 26.00% | 29.09% | 30.00% |
| 0.40 | 0.51 | 0.61 | 0.37 | 0.39 | 0.42 | |
| EPS in Rs | 2.67 | 3.40 | 4.07 | 2.20 | 1.71 | 1.84 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 14% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | -12% |
| TTM: | 40% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 6% |
| Last Year: | 5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.67 | 1.50 | 1.50 | 1.68 | 2.28 | 2.28 |
| Reserves | 0.72 | 0.35 | 0.88 | 1.87 | 6.55 | 6.97 |
| 0.54 | 0.89 | 1.03 | 0.87 | 0.00 | 0.36 | |
| 0.80 | 0.94 | 2.62 | 1.19 | 2.01 | 1.30 | |
| Total Liabilities | 2.73 | 3.68 | 6.03 | 5.61 | 10.84 | 10.91 |
| 0.84 | 1.65 | 1.33 | 1.71 | 2.12 | 2.18 | |
| CWIP | 0.08 | 0.41 | 0.56 | 0.94 | 1.01 | 0.99 |
| Investments | 0.09 | 0.14 | 2.02 | 0.07 | 0.07 | 0.08 |
| 1.72 | 1.48 | 2.12 | 2.89 | 7.64 | 7.66 | |
| Total Assets | 2.73 | 3.68 | 6.03 | 5.61 | 10.84 | 10.91 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 0.38 | 0.96 | 1.25 | -1.28 | -0.88 | -0.90 | |
| 0.54 | -1.47 | -0.65 | 0.75 | -0.73 | -0.44 | |
| -0.88 | 0.29 | 0.09 | 0.45 | 3.98 | 0.33 | |
| Net Cash Flow | 0.04 | -0.22 | 0.68 | -0.08 | 2.37 | -1.01 |
| Free Cash Flow | 0.19 | -0.55 | 0.97 | -2.49 | -1.73 | -1.45 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 64% | 109% | 114% | -115% | -87% | -70% |
Ratios
Standalone / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 44.92 | 20.60 | 28.17 | 34.22 | 68.30 | 71.23 |
| Inventory Days | 32.21 | 40.28 | 43.68 | 92.91 | ||
| Days Payable | 164.61 | 130.90 | 124.79 | 116.14 | ||
| Cash Conversion Cycle | -87.48 | -70.03 | -52.95 | 10.99 | 68.30 | 71.23 |
| Working Capital Days | 43.32 | -4.58 | -33.34 | 21.67 | 114.42 | 163.63 |
| ROCE % | 32.55% | 30.24% | 14.81% | 8.15% | 7.27% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Patients Handled count |
|
||||
| Plant and Machinery (Gross Block) INR Lakhs |
|||||
| Tests Conducted count |
|||||
| IPO Funds Utilized for Diagnostic Business Expansion INR Lakhs |
|||||
| Permanent Employees count |
|||||
| Multi-specialty Hospital Tie-ups Added count |
|||||
| New Service Centers Opened (Branches + Collection Centers) count |
|||||
| Revenue per Employee INR Lakhs per employee |
|||||
Extracted by Screener AI
Documents
Announcements
-
Non-Applicability Of Regulation 23 Of SEBI (LODR) Regulations, 2015 W.R.T Related Party Transactions
- PCS certificate confirms RPT provisions not applicable for H1 ended September 30, 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Regulation 74(5) filing for quarter ended September 30, 2026; no rematerialisation requests, shares fully in demat.
- Closure of Trading Window
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- 16th AGM resolutions approved; voting results and scrutinizer report submitted on September 24, 2026.
- Shareholder Meeting / Postal Ballot-Outcome of AGM
Business Overview:[1]
CTLL in the business of providing NABL
accredited healthcare services such as:
a) Pathology testing labs
b) Diagnostic centres
c) Scan centres
d) X-ray centres
e) ECG clinics